2013 Annual Meeting Archive Abstract Posters

2013 Annual Meeting Archive Abstract Posters

2013 Annual Meeting Archive > 2013 Annual Meeting Archive Abstract Posters

Poster Area 1: Abstracts 101 – 160

Breast Cancer, Cervical Cancer, Clinical Practice Issues, and Clinical Trial Design

Abstracts 101 – 102: Breast Cancer
Abstracts 103 – 135: Cervical Cancer
Abstracts 136 – 157: Clinical Practice Issues
Abstracts 158 – 160: Clinical Trial Design

Poster Area 2: Abstracts 161 – 233

Endometrial Cancer, Endometrial Cancer (Translational Research/Basic Science), Gynecologic Cancer – Screening/Prevention, and Health Care Reform

Abstracts 161 – 199: Endometrial Cancer
Abstracts 200 – 216: Endometrial Cancer (Translational Research/Basic Science)
Abstracts 217 – 224: Gynecologic Cancer Screening/Prevention
Abstracts 225 – 233: Health Care Reform

Poster Area 3: Abstracts 234 – 298

Hereditary Cancers, Novel Surgical Techniques, Ovarian Cancer, and Ovarian Cancer (Chemotherapy)

Abstracts 234 – 251: Hereditary Cancers
Abstracts 252 – 264: Novel Surgical Techniques
Abstracts 265 – 286: Ovarian Cancer
Abstracts 287 – 298: Ovarian Cancer (Chemotherapy)

Poster Area 4: Abstracts 299 – 369

Ovarian Cancer (Translational Research/Basic Science), Palliative Care, Public Health, Quality of Life, and Rare Tumors

Abstracts 299 – 334: Ovarian Cancer (Translational Research/Basic Science)
Abstracts 335 – 342: Palliative Care
Abstracts 343 – 348: Public Health
Abstracts 349 – 360: Quality of Life
Abstracts 361 – 369: Rare Tumors

Poster Area 5: Abstracts 370 – 401

Robotic Surgery, Translational Research/Basic Science, and Vulvar Cancer

Abstracts 370 – 389: Robotic Surgery
Abstracts 390 – 395: Translational Research/Basic Science
Abstracts 396 – 401: Vulvar Cancer

Abstracts 101- 102: Breast Cancer

101 – The role of breast-specific gamma imaging on preoperative and surgical management in women with newly diagnosed breast cancer
N. Jones1, D. Hetzel2, C. Harkness2, T. Vanderkwaak2, S. Galvin1, A. Case2
1Mountain Area Health Education Center, Asheville, NC, 2Hope Women’s Cancer Center, Asheville, NC

102 – An open label trial of SMK treatment of advanced metastatic cancer
S. Hoffman1, H. Bruckner2, G. Del Priore3, M. Demurjian1, K. Frankel1, J. Malanowska-Stega1
1Luminant Biosciences, West Caldwell, NJ, 2Bruckner Oncology, New York, NY, 3Indiana University, School of Medicine, Indianapolis, IN

Abstracts 103- 135: Cervical Cancer

103 – Utility of risk-weighted surgical-pathological factors in early-stage cervical cancer
K. Matsuo1, S. Mabuchi2, M. Okazawa3, T. Miyatake3, T. Enomoto2, S. Kamiura3, C. Morrow1, T. Kimura2
1University of Southern California, Los Angeles, CA, 2Osaka University, Suita, Japan, 3Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan

104 – Clinical results of external beam radiotherapy alone with a concomitant boost program or with conventional fractionation for cervical cancer patients who did not receive intracavitary brachytherapy
K. Matsuura1, T. Okabe1, K. Fujita2, H. Tanimoto3, Y. Akagi4, M. Kagemoto1
1Hiroshima City Hospital, Hiroshima, Japan, 2Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Japan, 3Hiroshima City Asa Hospital, Hiroshima, Japan, 4Hiroshima Heiwa Clinic, State of the Art Treatment Center, Hiroshima, Japan

105 – The multicenter collaborative study of small cell carcinoma of the uterine cervix in Japan
S. Kuji1, H. Nakayama2, S. Nishio3, O. Takeo4, Y. Nagamitsu5, N. Tanaka6, K. Ito7, Y. Hirashima8, N. Teramoto9, T. Yamada10
1Shizuoka Cancer Center, Shizuoka, Japan, 2Kanagawa Cancer Center, Kanagawa, Japan, 3Kurume University School of Medicine, Fukuoka, Japan, 4Tohoku University, Miyagi, Japan, 5Tokyo Medical University, Tokyo, Japan, 6Chiba Cancer Center, Chiba, Japan, 7Kansai Rosai Hospital, Hyogo, Japan, 8Shizuoka Cancer Center, Shizuoka, Japan, 9Shikoku Cancer Center, Ehime, Japan, 10Osaka Medical College, Osaka, Japan

106 – Cervical cancer prognosis in women aged 35 and younger
E. Pelkofski1, J. Stine2, N. Wages3, P. Gehrig2, K. Kim2, L. Cantrell1
1University of Virginia Health System, Charlottesville, VA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of Virginia, Charlottesville, VA

107 – Clinical correlation of nodal yield and disease recurrence in patients with early-stage cervical cancer
H. Cho, Y. Kim, J. No, K. Kim, S. Kim
Seoul National University Bundang Hospital, Seongnam, Kyeonggido, Republic of Korea

108 – Surveillance Epidemiology and End Results (SEER) analysis confirms overall survival benefit with concurrent chemoradiotherapy for cervical cancer
H. Hsu, J. Curtin, P. Schiff
New York University School of Medicine, New York, NY

109 – The socioeconomic and fiscal burden of cervix cancer in a modern era
C. Gunderson, E. Nugent, E. Bishop, D. McMeekin, K. Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK

110 – Cervical cancer post-treatment follow-up: Critical analysis
I. Hillesheim, M. Appel, R. Dos Reis, K. Rolim, A. Souza, L. Klimann, H. Monego
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

111 – Twists predict cervical carcinoma prognosis and promote metastasis through blocking senescence and inducing epithelial-mesenchymal transition
T. Wang1, Y. Li1, W. Wang2, Z. Wu3
1Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Wuhan, China, 2Southern Hospital, Guangzhou, China,34Hua Zhong of Science and Technology Affiliated Tongji Hospital, Wuhan, China

112 – Platinum-based combination chemotherapy ± consolidation versus weekly cisplatin during adjuvant concurrent chemoradiation after radical hysterectomy in early cervical cancer patients with pelvic lymph node metastasis
Y. Lee1, D. Bae1, C. Choi1, E. Jo1, H. Kim1, T. Kim1, B. Kim1, J. Lee1, J. Park1, M. Kim2
1Samsung Medical Center, Seoul, Republic of Korea, 2Samsung Changwon Hospital, Changwon, Republic of Korea

113 – Genetic profiling to predict recurrence of early cervical cancer
Y. Lee1, A. Yoon1, J. Park1, W. Kim2, M. Kim3, C. Choi1, T. Kim1, J. Lee1, B. Kim1, D. Bae1
1Samsung Medical Center, Seoul, Republic of Korea, 2Kangbuk Samsung Hospital, Seoul, Republic of Korea, 3Samsung Changwon Hospital, Changwon , Republic of Korea

114 – Comparison of laparoscopic-assisted radical vaginal hysterectomy and laparoscopic radical hysterectomy in the treatment of cervical cancer
C. Choi1, J. Lee2, Y. Lee2, H. Kim2, T. Kim2, D. Bae2, B. Kim2, W. Kim2, J. Park2, A. Yoon2
1Samsung Medical Center, Seoul, Republic of Korea, 2SMC, Seoul, Republic of Korea

115 – Clinical evaluation of early (stage I-II) cervical adenocarcinoma and adenosquamous cell carcinoma treated by radical surgery: What is the difference between squamous cell carcinoma and non-squamous cell carcinoma (non-SCC) of the cervix?
M. Mikami, M. Ikeda
Tokai University, School of Medicine, Isehara, Kanagawa, Japan

116 – Nanog-Tcl1a-Akt axis-induced tumor stem-like phenotype with immune evasion
H. Cho1, D. Chay2, J. Chung3, J. Kim1, S. Hewitt3, T. Wu4, T. Kim5
1Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 2Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea, 3National Cancer Institute, Bethesda, MD, 4Johns Hopkins Medical Institutions, Baltimore, MD, 5Graduate School of Medicine, Korea University, Ansan, Republic of Korea

117 – Single CpG Site hypomethylation of MAL gene might be associated with human papillomavirus persistent infection
S. Byun, E. Ki, J. Park
Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea

118 – Loss of ARID1A/BAF250a expression is associated with cervical carcinogenesis and predicts shorter overall survival
C. Lee1, H. Cho1, J. Chung2, S. Hewitt2, G. Yim3, E. Nam4, S. Kim3, Y. Kim3, J. Kim1
1Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 2National Cancer Institute, Bethesda, MD, 3Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 4Severance Hosptial, Yonsei University College of Medicine, Seoul, Republic of Korea

119 – Loupes assisted nerve-sparing abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer
A. Rodolakis1, N. Thomakos1, D. Haidopoulos1, G. Vlachos1, M. Sotiropoulou2, A. Antsaklis1
11st Department of Obstetrics and Gynecology, University of Athens, Gynecologic Oncology Unit -“Alexandra” Hospital, Athens, Greece 2Department of Pathology, University of Athens, Athens, Greece

120 – Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: Is less enough?
V. Andikyan, F. Khoury-Collado, J. Denesopolis, S. Sandadi, K. Park, C. Brown, Y. Sonoda, D. Chi, R. Barakat, N. Abu-Rustum
Memorial Sloan-Kettering Cancer Center, New York, NY

121 – Perioperative maternal morbidity among patients undergoing cesarean hysterectomy for cervical cancer: Are improved outcomes associated with the gynecologic oncologist?
K. Brookfield, J. Chapman, M. Norton, N. Teng
Stanford University Medical Center, Stanford, CA

122 – Concurrent chemoradiation with cisplatinum versus cisplatinum and fluorouracil in patients with cervical cancer
A. Roux1, J. Bazan2, E. Kidd2
1
Stanford Cancer Center, Palo Alto, CA, 2Stanford University Medical Center, Stanford, CA

123 – HPV16 methylation is a consistent biomarker of cervical intraepithelial neoplasia (CIN) 3 using a novel next-generation bisulfite-sequencing technology
M. Frimer1, A. Harari2, L. Mirabello3, Z. Chen4, N. Wentzensent3, P. Castle5, W. Kinney6, G. Goldberg1, M. Schiffman5, R. Burk1
1Division of Gynecologic Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY,3Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 4Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, 5National Cancer Institute, Bethesda, MD,6Permanente Medical Group, Sacramento, CA

124 – TRIO amplification and over-expression was associated with progression and prognosis of squamous cervical carcinoma
Z. Wu1, Y. Li1, T. Wang1, W. Wang2
1Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, HUST, Wuhan, China, 2Southern Hospital, Guangzhou, China

125 – HPV16 E6/E7 induces EMT via Twist and promotes carcinogenesis and metastasis of cervical cancer
Y. Li1, T. Wang2, W. Wang3, Z. Wu4
1The Department of Obstetrics and Gynecology, Tongji Hospital, Wuhan, China, 2Cancer Biology Research Center, Tongji Hospital, Wuhan, China, 3Southern Hospital, Guangzhou, China, 4Hua Zhong of Science and Technology Affiliated Tongji Hospital, Wuhan, China

126 – Comparison of laparoscopic versus abdominal radical hysterectomy for bulky (≥3 cm) FIGO stage IB and IIA cervical cancer
T. Kong, J. Lee, J. Paek, S. Chang, K. Chang, H. Ryu
Ajou University School of Medicine, Suwon, Republic of Korea

127 – Radical vaginal trachelectomy-fertility outcomes and significance of the lower uterine segment presence in the superior margin of the pathologic specimen
G. Miroshnichenko1, A. Covens2, J. Snelgrove3, Z. Ghorab2
1Univerisity of North Texas Health and Science Center, Fort Worth, TX, 2Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada, 3University of Toronto, Toronto, Ontario, Canada

128 – Outcomes of cold knife conization according to the margin involvement in high-grade lesions and microinvasive squamous cell carcinoma of the uterine cervix
T. Kong, J. Son, J. Paek, S. Chang, K. Chang, H. Ryu
Ajou University School of Medicine, Suwon, Republic of Korea

129 – Tailoring the parametrectomy in locally advanced cervical carcinoma: Is it feasible and safe?
V. Di Donato, P. Benedetti Panici, I. Palaia, A. Musella, S. Visentin, C. Bracchi, C. Marchetti, P. Giorgia, F. Bellati
Dep. Gynecologic Oncology – Sapienza University, Rome, Italy

130 – Less radical surgery possible in patients with stage IB1 cervical cancer
N. Thomakos1, D. Zacharakis2, D. Louradou2, A. Rodolakis2, N. Skampardonis2, M. Sotiropoulou3, D. Haidopoulos4, G. Vlachos4, A. Antsaklis4
1Alexandra University Hospital, Athens, Athens, Greece, 21st Department of Obstetrics and Gynecology, University of Athens, Alexandra Hospital, Athens, Greece, 3Department of Pathology, “Alexandra” Hospital, Athens, Greece, Athens, Greece, 41st Department of Obstetrics and Gynecology, University of Athens, Gynecologic Oncology Unit, Athens, Greece

131 – The clinical significance of beta adrenergic receptor expression in cervical cancer tissue
L. Ramondetta1, Y. Kang1, W. Hu1, C. Sun1, M. Kott2, M. Deavers1, A. Klopp1, P. Thaker3, J. Smith1, A. Sood1
1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas, Houston, Houston, TX, 3Washington University, St. Louis, MO

132 – Distance traveled for treatment of cervix cancer: Who travels the furthest and does it impact outcome?
C. Gunderson, E. Nugent, E. Bishop, D. McMeekin, K. Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK

133 – A cost analysis of colposcopy following abnormal cytology in post-treatment surveillance for cervical cancer
A. Tergas1, L. Havrilesky2, S. Guntupalli3, W. Huh4, L. Massad3, A. Nickles Fader1, B. Rimel5
1Johns Hopkins University Hospital, Baltimore, MD, 2Duke University Medical Center, Durham, NC, 3Washington University, St. Louis, MO, 4UAB Comprehensive Cancer Center, Birmingham, AL, 5Cedars Sinai Medical Center, Los Angeles, CA

134 – Outcomes of locally advanced cervical cancer in an underserved indigent US population
A. Moron1, D. Manders2, C. Nagel2, D. Miller2, D. Richardson2, S. Kehoe2, K. Albuquerque2, J. Lea2
1UT Southwestern Medical Center, Dallas, TX, 2University of Texas Soutwestern, Dallas, TX

135 – Abdominal radical trachelectomy (ART) for cervical malignancies: Fertility outcomes in 124 Chinese patients
X. Wu, J. Li
Fudan University Shanghai Cancer Center, Shanghai, China

Abstracts 136- 157: Clinical Practice Issues

136 – Predictive model of venous thromboembolism in endometrial cancer
K. Matsuo, E. Wu, A. Yessaian, Y. Lin, H. Pham, L. Muderspach, H. Liebman, C. Morrow, L. Roman
University of Southern California, Los Angeles, CA

137 – Clinical factors predictive of postoperative pulmonary embolism in gynecologic cancer patients
C. Albertin, S. Uppal, A. Al Niami, J. Hinshaw, S. Seo, E. Hartenbach
University of Wisconsin, Madison, WI

138 – Defining practice patterns: What is “standard” postoperative care? A survey of the SGO membership
E. Stevens, C. Pardo, Y. Lee, O. Abulafia
SUNY/Downstate Medical Center, Brooklyn, NY

139 – Abstract Withdrawn at Authors Request

140 – Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Does cost really matter?
C. Gunderson, B. Dinh, R. Farrell, E. Thomas, S. Vesely, S. Chopra, D. McMeekin, K. Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK

141 – Effectiveness of cyanoacrylate microbial sealant (CMS) in the reduction of surgical site infection in gynecologic oncology procedures: A single-center randomized study: interim analysis
E. Thomas, E. Nugent, D. McMeekin, J. Walker, L. Landrum, K. Moxley, E. Bishop, C. Mathews, K. Moore
University of Oklahoma, Oklahoma City, OK

142 – Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis
C. Billingsley1, D. Cohn1, A. Crim1, D. O’Malley1, L. Havrilesky2
1The Ohio State University, Columbus, OH, 2Duke University Medical Center, Durham, NC

143 – Revolving door of obstruction – An analysis of gynecologic oncology readmission
S. Phelps, V. Andikyan, J. Denesopolis, E. Rodriguez, W. Tew, S. Martin, W. Hoskins, R. Barakat, D. Chi, V. Makker
Memorial Sloan-Kettering Cancer Center, New York, NY

144 – Prospective evaluation of postoperative pain and quality of recovery in patients undergoing robotic vs. laparotomy for staging of endometrial cancer
D. Tulman, L. Huffman, S. Bergese, J. Fowler, D. O’Malley, R. Salani, E. Eisenhauer, L. Copeland, D. Cohn
The Ohio State University, Columbus, OH

145 – Routine cystoscopy after robotic gynecologic oncology surgery: Are we increasing urinary injury detection or simply achieving medical-legal benefit?
M. Nguyen1, C. LaFargue1, M. Karsy1, E. Stevens2, S. McKernan1, T. Pua1, C. Gorelick3, S. Tedjarati1, T. Pradhan1
1New York Medical College/Westchester Medical Center, Hawthorne, NY, 2SUNY/Downstate Medical Center, Brooklyn, NY, 3New York Methodist Hospital/Cornell Medical College Affiliate, Brooklyn, NY

146 – Postoperative wound separation among obese women
T. Bass, R. Miller, S. Slone, F. Ueland, L. Baldwin, J. Hoff, J. Elder, C. DeSimone
University of Kentucky Medical Center, Lexington, KY

147 – A silent threat: The prevalence of undiagnosed obstructive sleep apnea among gynecologic oncology patients
M. Courtney-Brooks1, M. Barrett2, L. Cantrell2
1University of Virginia, Charlottesville, VA, 2University of Virginia Health System, Charlottesville, VA

148 – Postoperative pain control in the gynecologic laparotomy patient: A prospective, randomized comparison of acetaminophen with narcotics vs. ketorolac with narcotics
J. Rakowski, C. Jeppson, J. James, S. Ahmad, G. Bigsby IV, G. Ghurani, R. Holloway, J. Kendrick IV
Florida Hospital Cancer Institute, Orlando, FL

149 – A single institution review of continuous epidural infusion anesthesia and analgesia in gynecologic oncology patients
M. Courtney-Brooks, C. Tanner Kurtz, E. Pelkofski, J. Nakayama, L. Duska
University of Virginia Health System, Charlottesville, VA

150 – A cost-analysis of anastomotic leak vs. prophylactic bowel diversion at the time of large bowel resection for primary ovarian cancer
E. Kalogera, L. Haas, B. Borah, S. Dowdy, W. Cliby
Mayo Clinic, Rochester, MN

151 – A prospective study to evaluate diffusion weighted MRI (DW-MRI) imaging in the detection of peritoneal carcinomatosis
S. Yamada, E. Lengyel, M. Tenney, S. Thomas, A. Oto
University of Chicago, Chicago, IL

152 – Lower extremity edema after primary radiotherapy versus radiotherapy after pretreatment laparoscopic surgical staging in locally advanced cervical cancer
M. Lim, J. Lee, H. Yoo, S. Seo, S. Kang, J. Kim, S. Park
National Cancer Center, Goyang-si, Republic of Korea

153 – Excess risk of Clostridium difficile enterocolitis in ovarian cancer is related to exposure to broad-spectrum antibiotics
J. Kim, K. Ward, N. Shah, C. Saenz, M. McHale, S. Plaxe
UCSD- The Moores Cancer Center, La Jolla, CA

154 – Surgical “Apgar” score identifies a population of women with gynecologic cancer at high risk for surgical morbidity
R. Clark1, M. Lee2, L. Bradford2, D. Boruta2, M. Del Carmen2, J. Schorge2, A. Goodman2, W. Growdon2
1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA

155 – Comparison of outcomes in patients undergoing rectosigmoid resection: End colostomy versus reanastomosis
M. Quimper, J. Lesnock, S. Beriwal, T. Krivak, A. Olawaiye, J. Lin, P. Sukumvanich
Magee-Women’s Hospital of UPMC, Pittsburgh, PA

156 – Burdens of the gynecologic literature
E. Pavlik, M. Schwartz
University of Kentucky Medical Center/Markey Cancer Center, Lexington, KY

157 – Perioperative venous thromboembolism is rare after minimally invasive surgery for endometrial and cervical cancer: A multi institutional study
S. Kumar1, J. Woelk2, Z. Al-Wahab3, S. Sarangi2, R. Morris2, A. Munkarah4, S. Dowdy2, A. Mariani2, W. Cliby2
1Mayo Clinic College of Medicine, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Wayne State University, Detroit, MI, 4Henry Ford Health System, Detroit, MI

Abstracts 158 – 160: Clinical Trial Design

158 – Phase 0 studies in gynecologic malignancies are feasible and acceptable to patients
L. Duska, H. Lothamer, W. Faust, G. Petroni, P. Fracasso, S. Parsons
University of Virginia, Charlottesville, VA

159 – Trial design and endpoint definition for conservative management of endometrial neoplasia
S. Blank, J. Greenwald, L. Boyd, B. Pothuri, J. Curtin
New York University School of Medicine, New York, NY

160 – Characteristics and outcomes of platinum-resistant patients treated in a phase I clinic
K. Slaughter, B. James, E. Nugent, E. Bishop, L. Perry, D. McMeekin, K. Moore
The University of Oklahoma, Oklahoma City, OK

Abstracts 161 – 199: Endometrial Cancer

161 – Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis
W. Joo1, D. Silasi2, E. Ratner2, A. Santin2, M. Azodi2, T. Rutherford2, P. Schwartz2
1CHA University, Seoul, Republic of Korea, 2Yale University School of Medicine, New Haven, CT

162 – Costs of incorporating computer-based surgical platforms in the management of patients with newly diagnosed uterine cancers
M. Leitao, A. Bartashnik, I. Wagner, S. Lee, A. Caroline, H. Thaler, N. Abu-Rustum, E. Jewell, R. Barakat, G. Gardner
Memorial Sloan-Kettering Cancer Center, New York, NY

163 – Prospective lifestyle modification in patients with good prognosis endometrioid adenocarcinoma of the uterus
E. Nugent1, R. Wild2, K. Moxley2, T. Nelson2, E. Bishop2, C. Mathews2, J. Walker2, L. Landrum2, D. McMeekin2, K. Moore2
1University of Oklahoma HSC, Oklahoma City, OK, 2University of Oklahoma, Oklahoma City, OK

164 – Lymphadenectomy in women with early-stage intermediate-to high-risk endometrial cancer (HIR-EC) decreases local recurrence but not overall recurrence or survival: A retrospective cohort study
L. Weinberg1, C. Kunos2, K. Zanotti2
1Cleveland Clinic Foundation, Cleveland, OH, 2Case Western Reserve – Mac Donald Women’s Hospital, Cleveland, OH

165 – Fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin
A. Simpson1, T. Feigenberg2, B. Clarke3, L. Gien4, N. Ismiil5, S. Laframboise2, C. Massey6, S. Ferguson2
1University of Toronto, Toronto, Ontario, Canada, 2Princess Margaret Hospital, Toronto, Ontario, Canada, 3Toronto General Hospital, Toronto, Ontario, Canada, 4Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada, 5Sunnybrook Health Sciences Center, Toronto, Ontario, Canada, 6Independent, Toronto, Ontario, Canada

166 – The significance of positive peritoneal cytology in stage III endometrial cancer
S. Milgrom, M. Kollmeier, N. Abu-Rustum, V. Makker, G. Gardner, R. Barakat, K. Alektiar
Memorial Sloan-Kettering Cancer Center, New York, NY

167 – Risk of uterine malignancy (UM) increases proportionally with increasing body mass index (BMI)
K. Ward, N. Shah, M. Davis, C. Saenz, M. McHale, S. Plaxe
UCSD- The Moores Cancer Center, La Jolla, CA

168 – Surgical staging for uterine papillary serous carcinoma: Is omentectomy really necessary?
R. Eitan1, A. Gershoni2, G. Sabah2, Y. Peled2, H. Levavi2
1Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, 2Tel-Aviv University, Tel-Aviv, Israel

169 – Tumor diameter and preoperative CA-125 level evaluation for high-risk endometrial cancer patients
C. Andrade, G. Carrara, M. Vieira, M. Cadamuro, M. Mengatto, J. Fregnani, A. Tsunoda
1Barretos Cancer Hospital, Barretos, São Paulo, Brazil

170 – Prognostic value of positive cytology in endometrial cancer
G. Baiocchi, M. Macedo, L. Badiglian-Filho, L. De Brot, C. Faloppa, E. Fukazawa, L. Kumagai, C. Osorio
AC Camargo Cancer Hospital, Sao Paulo, Brazil

171 – Endometrial cancer lesion size is predictive of disease recurrence and long-term survival
C. DeSimone, J. Elder, A. Edwards, S. Slone, J. Feddock, R. Miller, L. Baldwin, J. van Nagell, Jr, F. Ueland
University of Kentucky Medical Center, Lexington, KY

172 – Uterine washing biomarkers as a novel screening tool for high-grade serous carcinoma
C. St. Clair, J. Ducie, Q. Zhou, F. Dao, N. Kauff, D. Spriggs, M. Fleisher, A. Iasonos, D. Levine
Memorial Sloan-Kettering Cancer Center, New York, NY

173 – Regional variation in postoperative radiation therapy (PORT) for early endometrial cancer (EC)
T. Korenaga, K. Ward, M. McHale, C. Saenz, S. Plaxe
UCSD – The Moores Cancer Center, La Jolla, CA

174 – The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma
L. Eiriksson1, H. Kaur2, N. Ismiil3, L. Barbera3, A. Covens3
1University of Toronto, Toronto, Ontario, Canada, 2McMaster University, Hamilton, Ontario, Canada, 3Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

175 – A comparison of outcomes in patients with early-stage mucinous endometrial and endometrioid endometrial cancer with and without adjuvant therapy
S. Owusu-Darko1, J. Rauh-Hain2, L. Bradford2, M. Worley3, N. Horowitz3, J. Schorge2, A. Goodman2, M. Del Carmen2
1Brigham and Women’s Hospital, Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA, 3Brigham & Women’s Hospital, Boston, MA

176 – Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging
C. Kim, E. Barber, F. Khoury-Collado, J. Barlin, K. Park, Y. Sonoda, M. Hensley, D. Chi, R. Barakat, N. Abu-Rustum
Memorial Sloan-Kettering Cancer, New York, NY

177 – Does para-aortic lymph node assessment during endometrial cancer staging impact overall survival?
J. Barlin, Q. Zhou, C. St. Clair, A. Iasonos, R. Soslow, K. Alektiar, M. Leitao, D. Chi, R. Barakat, N. Abu-Rustum
Memorial Sloan-Kettering Cancer Center, New York, NY

178 – Redefining stage I endometrial cancer: Incorporating histology, grade, myoinvasion, and whether or not lymph nodes were removed
J. Barlin, M. Lutz, Q. Zhou, C. St. Clair, M. Leitao, A. Iasonos, R. Barakat, X. Matias-Guiu, R. Soslow, N. Abu-Rustum
Memorial Sloan-Kettering Cancer Center, New York, NY

179 – Use of metformin is associated with improved endometrial cancer survival
N. Nevadunsky, A. Van Arsdale, G. Kaur, M. Frimer, E. Conroy, M. Einstein, G. Goldberg
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

180 – Application of propensity score model to examine the prognostic significance of uterine clear cell versus uterine serous carcinoma
O. Gayar, S. Patel, C. Cogan, T. Buekers, A. Munkarah, M. Elshaikh
Henry Ford Health System, Detroit, MI

181 – The impact of tumor size and location in high-grade endometrial cancer patients undergoing minimally invasive surgery
K. Doll1, J. Tseng2, A. Nickles Fader2, P. Gehrig1
1University of North Carolina School of Medicine, Chapel Hill, NC, 2Johns Hopkins Medical Institutions, Baltimore, MD

182 – Treatment-related outcomes in patients with stage III-IV endometrial cancer treated with chemotherapy with or without the addition of radiation therapy
S. Munns1, A. Semaan1, S. Seward1, A. Munkarah2, P. Paximadis1, S. Miller1, R. Ali1, R. Morris1
1Wayne State University, Detroit, MI, 2Henry Ford Health System, Detroit, MI

183 – Is body mass index a prognostic factor in patients with early-stage type II endometrial cancer?
R. Jalloul1, Z. Al-Wahab2, M. Alshaikh1, T. Buekers1, M. Mahan1, R. Hanna1
1Henry Ford Health System, Detroit, MI, 2Wayne State University, Detroit, MI

184 – Occult uterine cancer in patients undergoing laparoscopic hysterectomy with morcellation: Implications for surveillance for disease recurrence and outcomes
M. Rowland1, J. Lesnock2, R. Edwards1, S. Richard3, K. Zorn1, P. Sukumvanich1, T. Krivak1
1Magee Women’s Hospital of UPMC, Pittsburgh, PA, 2Mid-Atlantic Gynecologic Oncology of MonGeneral Hospital, Morgantown, WV, 3Hahnemann University Hospital, Philadelphia, PA

185 – Preoperative tumor grade and intraoperative tumor size identifies patients at intermediate risk for lymph node involvement but not necessarily those at increased risk of recurrence
K. Rath, G. McCann, A. Clements, F. Backes, R. Salani, J. Fowler, E. Eisenhauer, D. Cohn, L. Copeland, D. O’Malley
The Ohio State University, Columbus, OH

186 – Clinical nomogram to predict for para-aortic lymph node metastasis in advanced-stage endometrial cancer patients
B. Bavan1, R. Popat1, K. Blansit2, T. Kiet2, R. Brooks2, L. Chen2, S. Ueda2, D. Kapp1, J. Chan2
1Stanford University Medical Center, Stanford, CA, 2UCSF Comprehensive Cancer Center, San Francisco, CA

187 – Are postmenopausal women with body mass indices <30 with grade 1 endometrial cancer more likely than their obese counterparts to have advanced or recurrent disease?
A. Clements, F. Backes, K. Rath, G. McCann, D. Cohn, J. Fowler, L. Copeland, R. Salani, E. Eisenhauer, D. O’Malley
The Ohio State University, Columbus, OH

188 – Importance of platinum sensitivity and treatment modality in advanced-stage uterine papillary serous carcinoma
L. Holman, P. Soliman, N. Pal, N. Balakrishnan, A. Klopp, R. Broaddus, N. Fleming, M. Munsell, K. Lu, S. Westin
The University of Texas, MD Anderson Cancer Center, Houston, TX

189 – Assessment of the accuracy of preoperative and intraoperative endometrial pathology in uterine carcinoma
C. Nagel, B. Davidson, K. Elwell, C. Bevan, D. Richardson, S. Kehoe, J. Lea, D. Miller
University of Texas Southwestern Medical Center, Dallas, TX

190 – Can preoperative factors predict the need for postoperative radiation in patients with endometrioid adenocarcinoma of the uterus?
C. Nagel, B. Davidson, K. Elwell, C. Bevan, D. Richardson, S. Kehoe, J. Lea, D. Miller
University of Texas Southwestern Medical Center, Dallas, TX

191 – A phase II study of multimodal optical imaging to evaluate tumor margins for potential use in conservative, uterine-sparing surgery for women with endometrial cancer
P. Ramirez1, R. Broaddus1, M. Frumovitz1, K. Schmeler1, S. Westin1, M. Munsell1, A. Matamoros1, T. Quang2, J. Dobbs2, R. Richards-Kortum2
1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Rice University, Houston, TX

192 – Multiethnic/racial differences in risk factors and overall survival in endometrial carcinoma
H. Smith1, E. Prossnitz2, H. Arias-Pulido2, T. Ford1, C. Qualls2
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2University of New Mexico, Albuquerque, NM

193 – Neoadjuvant chemotherapy in stage IV uterine papillary serous carcinoma
L. Holman, P. Soliman, N. Pal, H. Mhadgut, A. Klopp, R. Broaddus, N. Fleming, M. Munsell, K. Lu, S. Westin
The University of Texas, MD Anderson Cancer Center, Houston, TX

194 – Identifying a subgroup of endometrial cancer patients who may potentially forego para-aortic lymphadenectomy
S. Kumar1, A. Mariani2, J. Bakkum-Gamez2, A. Weaver2, M. Mc Gree2, W. Cliby2, K. Podratz2, S. Dowdy2
1Mayo Clinic College of Medicine, Rochester, MN, 2Mayo Clinic, Rochester, MN

195 – Redefining obesity, diabetes, and race in type I and type II endometrial cancers
E. Ko1, P. Walter2, L. Clark1, L. Havrilesky2, A. Alvarez-Secord2, P. Gehrig1, V. Bae-Jump1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Duke University Medical Center, Durham, NC

196 – Metformin reduces recurrence and improves survival in endometrial cancers
E. Ko1, W. Paige2, L. Clark3, A. Jackson3, J. Franasiak3, L. Havrilesky2, A. Alvarez-Secord2, P. Gehrig1, V. Bae-Jump1
1University of North Carolina School of Medicine, Chapel Hill, NC, 2Duke University Medical Center, Durham, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

197 – Recurrences patterns following robotic-assisted surgical staging for endometrial carcinoma
J. Kilgore, A. Jackson, E. Ko, K. Schuler, J. Boggess
University of North Carolina School of Medicine, Chapel Hill, NC

198 – Does comprehensive staging make a difference for recurrence and survival of patients with high-intermediate risk endometrial cancer?
F. Backes, L. Huffman, R. Farrell, L. Copeland, R. Salani, E. Eisenhauer, D. O’Malley, D. Cohn, J. Fowler
The Ohio State University, Columbus, OH

199 – Does adjuvant therapy improve survival for early stage leiomyosarcoma?
S. Ricci1, R. Giuntoli2, M. Lopez Acecevdo3, E. Eisenhauer4, H. Frasure5, P. Gehrig6, A. Alvarez-Secord3, T. Diaz-Montes2, E. Tanner2, A. Nickles Fader2
1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 3Duke University Medical Center, Durham, NC, 4The Ohio State University, Columbus, OH, 5Case Western Reserve – Mac Donald Women’s Hospital, Cleveland, OH, 6University of North Carolina at Chapel Hill, Chapel Hill, NC

Abstracts 200 – 216: Endometrial Cancer (Translational Research/Basic Science)

200 – The effect of loss of mismatch repair gene expression on survival for patients with high risk endometrial cancer
K. Terada1, M. Black2, J. Davis3, L. Terada2, D. Shimizu2
1University of Hawaii at Manoa, Honolulu, HI, 2Queens Medical Center, Honolulu, HI, 3University of Hawaii, Honolulu, HI

201 – ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinoma
H. Smith1, C. Qualls2, G. Huang1, H. Arias-Pulido2, T. Howard2, N. Joste2, A. Van Arsdale1, E. Prossnitz2
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2University of New Mexico, Albuquerque, NM

202 – Biomarkers associated with metabolic syndrome, endometrioid adenocarcinoma (EC) of the uterus, and disease prognosis
E. Nugent1, D. Benbrook2, A. Long2, K. Moxley2, R. Wild2, D. McMeekin2
1University of Oklahoma HSC, Oklahoma City, OK, 2University of Oklahoma, Oklahoma City, OK

203 – The role of ABCG2 and other stem cell markers in tumorigenesis and chemoresistance – An analysis of fresh uterine tumor specimens
J. Chan1, A. Sherman2, J. Shin2, T. Kiet2, K. Blansit2, L. Hu2
1UCSF Comprehensive Cancer Center, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA

204 – Stathmin expression in endometrial hyperplasia: A potential marker for cancer progression
E. Dickson1, W. Ricketts2, A. Jonson1, P. Judson Lancaster3
1University of Minnesota, Minneapolis, MN, 2OvaGene Oncology, Irvine, CA, 3University of South Florida College of Medicine, Tampa, FL

205 – Estrogen receptor expression as a useful clinical prognosticator in early-stage uterine serous carcinoma
J. Hou, M. Frimer, E. Conroy, X. O’Leary, K. Whitney, M. Einstein, G. Goldberg
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

206 – The role of the Yes kinase-associated protein as a proto-oncogene in endometrial cancer
T. Bickley, M. Sudol, V. Mazack, H. Sun, J. Nash, H. Kaspar, R. Gogoi
Geisinger Health System, Danville, PA

207 – HAND2 expression is increased in endometrial hyperplasia/cancer
J. Franasiak, J. Hubbs, M. Olorvida, S. Young, P. Gehrig, V. Bae-Jump
University of North Carolina School of Medicine, Chapel Hill, NC

208 – Wnt pathway gene expression and association with clinicopathologic characteristics in endometrial cancer – An analysis of The Cancer Genome Atlas (TCGA)
T. Dellinger1, C. Warden1, E. Han2, M. Wakabayashi2
1City of Hope National Comprehensive Cancer Center, Duarte, CA, 2City of Hope Medical Group, Duarte, CA

209 – Iron-modified albumin in cervical-vaginal fluid may lead to a screening test for endometrial cancer
M. Finan1, L. Pannell1, D. Billheimer2, L. Schambeau1, J. Blandford1, R. Rocconi1
1USA Mitchell Cancer Institute, Mobile, AL, 2University of Arizona, Tucson, AZ

210 – A novel marker for the management of women diagnosed with endometrial adenocarcinoma of the uterus
R. Moore1, C. Miller1, T. Horan1, R. Singh1, N. Kawar1, E. Eklund1, G. Lambert-Messerlian1, C. McCourt1, D. Hawkins2, C. Granai1
1Women & Infants Hospital Brown University, Providence, RI, 2University of Minnesota, Minneapolis, MN

211 – Cation-selective transporters are critical to the anticancer efficacy of metformin in endometrial cancer
E. Damery, Y. Zhang, R. Everett, V. Bae-Jump, D. Thakker
University of North Carolina School of Medicine, Chapel Hill, NC

212 – Phenformin suppresses proliferation and induces apoptosis in endometrial cancer cell lines
A. Jackson, J. Kilgore, H. Qiu, C. Zhou, P. Gehrig, V. Bae-Jump
University of North Carolina School of Medicine, Chapel Hill, NC

213 – The role of estrogen and Wnt signaling in endometrial carcinoma
P. Dholakiya, T. Neff, D. Bender, A. Ahmed, K. De Geest, S. Park, M. Goodheart
University of Iowa Hospitals and Clinics, Iowa City, IA

214 – Comparison of FIGO grade 3 endometrioid endometrial carcinomas with type 2 uterine cancers. Can grade 3 tumors be classified as type 2 cancers? A clinicopathological and immunohistochemical analysis
M. Nguyen, L. Han, T. Pua, A. Mares, M. Karsy, C. LaFargue, O. Ardacheva, T. Pradhan, J. Fallon, S. Tedjarati
New York Medical College/Westchester Medical Center, Hawthorne, NY

215 – Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis
A. Ahmad1, S. Ahmad2, J. Weidhaas2, P. Hui2, A. Santin2, M. Azodi2, D. Silasi2, P. Schwartz2, T. Rutherford2, E. Ratner2
1Yale New Haven Hospital, New Haven, CT, 2Yale University School of Medicine, New Haven, CT

216 – A uterine-specific PIK3CA and PTEN dual mutation signature is associated with poor prognosis
W. Growdon, T. Johnson, V. Byron, R. Foster, R. Tambouret, J. Schorge, R. Penson, B. Rueda, D. Borger
Massachusetts General Hospital/Harvard University, Boston, MA

Abstracts 217 – 224: Gynecologic Cancer Screening/Prevention

217 – Achievable balanced costs in ovarian cancer screening using serial transvaginal ultrasound by preventing progression
E. Pavlik, R. Miller, F. Ueland, C. DeSimone, J. Elder, J. Hoff, J. VanNagell
University of Kentucky Medical Center/Markey Cancer Center, Lexington, KY

218 – The role of endocervical curettage with colposcopy in HIV-positive (+) patients as compared to HIV-negative (-) patients: A retrospective analysis of 2,591 colposcopic visits from the Women’s Interagency HIV study
T. Pradhan1, Y. Chak2, R. Wright3, C. Colie4, L. Sanchez-Keeland5, T. Darragh6, L. Massad7, G. D’Souza8, Y. Lee2
1Westchester Medical Center/New York Medical College, Hawthorne, NY , 2State University of New York/Downstate Medical Center, Brooklyn, NY, 3Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 4Medstar Georgetown University Hospital, Washington, DC, 5University of Southern California, Los Angeles, CA, 6UCSF-Mount Zion Medical Center, San Francisco, CA, 7University of Washington School of Medicine, St. Louis, MO, 8Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

219 – Monitoring ovarian tumors using serial ultrasound with tumor morphology index
J. Elder, A. Long, R. Miller, W. Ueland, C. DeSimone, J. Hoff, R. Kryscio, J. van Nagell, Jr, E. Pavlik, F. Ueland
University of Kentucky, Lexington, KY

220 – Pre-operative imaging of granulosa cell tumors in combination with CA-125 as a predictor of malignancy
J. Stine1, A. Suri1, B. Erickson2, M. Chiu1, P. Gehrig1, M. Conner2, W. Huh2, K. Kim1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of Alabama at Birmingham, Birmingham, AL

221 – Retrospective analysis of glandular cells on vaginal cytology smears in women with a previous hysterectomy
J. Heim, M. Klobocista, S. Khader, G. Goldberg
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

222 – Risk-reducing salpingectomy at the time of benign hysterectomy and permanent sterilization: A survey of obstetricians/gynecologists
M. Frey1, J. Kramer2, T. Caputo2, V. Gunnala2, K. Holcomb2, M. Tsatsas3, D. Gupta2
1New York Presbyterian Weill Cornell Medical Center, New York, NY, 2New York Presbyterian Medical Center, New York, NY, 3New York Hospital Queens, Fresh Meadows, NY

223 – Routine bilateral salpingectomy at the time of hysterectomy with ovarian preservation
V. Rodriguez- Triana1, S. Park2, M. Amneus2, C. Holschneider2
1UCLA, Los Angeles, CA, 2Olive View-UCLA Medical Center, Sylmar, CA

224 – Do updated Pap smear screening guidelines prevent the expeditious diagnosis of invasive cervical cancer?
C. Nitschmann, J. Mirkovic, T. May, S. Feldman
Brigham and Women’s Hospital, Boston , MA

Abstracts 225 – 233: Health Care Reform

225 – Feasibility study of tubal lavage as an early ovarian cancer detection method
M. de Leon, Y. Xu, A. Hassan Hamed, G. Del Priore
Indiana University School of Medicine, Indianapolis, IN

226 – A new model for provider/insurer relations in gyn oncology
P. Timmins1, K. Panneton2
1Women’s Cancer Care Associates, Albany, NY, 2Capital District Physicians Health Plan, Albany, NY

227 – Can molecular profiling increase the ability to provide cost effective health care in gynecologic oncology?
A. Walter, K. Wood, K. Manahan, J. Geisler
University of Toledo Medical Center, Toledo, OH

228 – Insurance and geography affect access to care at an NCI-designated cancer center
S. Fleming1, S. Amrane2, G. Rao1, S. Temkin1
1University of Maryland, Baltimore, MD, 2University of Maryland Medical System, Baltimore, MD

229 – Patient, care, and discharge factors associated with risk of hospital readmission after surgical cytoreduction for ovarian carcinoma
R. Clark, W. Growdon, A. Wiechert, M. Del Carmen, A. Goodman, D. Boruta, L. Bradford, J. Rauh-Hain, J. Schorge
Massachusetts General Hospital/Harvard University, Boston, MA

230 – Trends in hospital volume and patterns of referral for women with gynecologic cancers
J. Wright1, T. Herzog2, W. Burke2, Y. Lu2, S. Lewin2, A. Neugut2, D. Hershman2
1Columbia University, New York, NY, 2Columbia University College of Physicians and Surgeons, New York, NY

231 – Referral patterns and association with excessive imaging and delays to surgical treatment among patients with gynecologic malignancies
G. Miroshnichenko1, R. Kupets2, L. Paszat2
1Univerisity of North Texas Health and Science Center, Fort Worth, TX, 2Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada

232 – FDA approval of oncology drugs in association of relative survival benefits – An analysis of the oncology drug applications over the 10 years
N. Young-Lin1, I. Amanam1, T. Kiet1, K. Blansit1, D. Kapp2, B. Monk3, D. Hoth1, J. Chan1 1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 2Stanford University Medical Center, Stanford, CA, 3Creighton University School of Medicine, Omaha, NE

233 – Racial disparities and patterns of ovarian cancer surgical care in California
F. Liu, R. Bristow
UC Irvine Medical Center, Orange, CA

Abstracts 234 – 251: Hereditary Cancers

234 – Timing of genetic counselling in patients with ovarian, fallopian tube, or primary peritoneal carcinoma
A. Novetsky, K. Smith, S. Babb, D. Jeffe, A. Hagemann, P. Thaker, M. Powell, D. Mutch, L. Massad, I. Zighelboim
Washington University School of Medicine, St. Louis, MO

235 – Evaluation of immune function in patients with hereditary cancers
L. Parker1, H. Strickland2, D. Clark1, D. Metzinger1, M. Milam1, D. Taylor1, C. Gercel-Taylor1
1University of Louisville, Louisville, KY, 2Naval Medical Center San Diego, San Diego, CA

236 – Screening endometrial cancer for Lynch syndrome in a Brazilian public health care system cancer center
C. Andrade, M. Mengatto, M. Vieira, M. Cadamuro, E. Palmero, J. Oliveira, P. Bogiss, D. Viana, A. Tsunoda
Barretos Cancer Hospital, Barretos, Brazil

237 – Endometrial cancer screening in Lynch syndrome: Do patients report symptoms prior to diagnosis?
K. Ring, S. Boyd-Rogers, Y. Amin, M. Daniels, B. Batte, K. Schmeler, E. Keeler, K. Lu
The University of Texas, MD Anderson Cancer Center, Houston, TX

238 – Diagnostic value of microsatellite instability analysis in uterine cavity washings to detect endometrial cancer in Lynch syndrome
A. Bats, H. Blons, C. Narjoz, M. Le Frère-Belda, P. Laurent-Puig, F. Lecuru
Hôpital Européen Georges-Pompidou, Paris, France

239 – Diagnostic value of diagnostic hysteroscopy for gynecologic screening in Lynch syndrome: Office vs general anaesthesia
N. Douay-Hauser1, C. Cellier1, A. Bats1, C. Huchon2, C. Bensaïd1, L. Makke1, P. Laurent-Puig1, A. Achouri1, M. Le Frère-Belda1, F. Lecuru1
1European Georges Pompidou Teaching Hospital, Paris, France, 2Centre Hospitalier Intercommunal de Poissy – Saint-Germain, Poissy, France

240 – Lynch syndrome screening strategies in low-risk endometrial cancer patients for the prevention of secondary colorectal cancers: A cost-effectiveness analysis
R. Rocconi1, J. Scalici1, C. Leath2, M. Finan1, J. Estes2, J. Straughn2
1University of South Alabama-Mitchell Cancer Institute, Mobile, AL, 2University of Alabama at Birmingham, Birmingham, AL

241 – The incidence of occult cancer in specimens from patients with genetic predisposition to ovarian and fallopian tube cancer
L. Douglass, G. Rodriguez, C. Kirschner, J. Hurteau
University of Chicago, Chicago, IL

242 – Best practices in risk-reducing bilateral salpingo-oophorectomy: The influence of surgical specialty
D. Malacarne1, Y. Long1, L. Boyd1, R. Wallach1, B. Pothuri1, D. Fishman2, J. Curtin1, S. Blank1
1New York University School of Medicine, New York, NY, 2Mount Sinai School of Medicine, New York, NY

243 – Ten-year experience with a multidisciplinary high-risk program
H. Hinshaw1, N. Engel2, E. Sampene3, K. Zorn1
1Magee-Women’s Hospital of UPMC, Pittsburgh, PA, 2Cancer Genetics Program, University of Pittsburgh Cancer Center, UPMC, Pittsburgh, PA, 3Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA

244 – When you hear hoof beats, don’t forget the zebra: The role of nonserous ovarian cancer in BRCA mutation carriers
K. Ring, M. Daniels, B. Batte, K. Lu
The University of Texas, MD Anderson Cancer Center, Houston, TX

245 – Does postmenopausal risk-reducing salpingo-oophorectomy reduce the risk of BRCA-associated breast cancer?
J. Barlin, M. Pike, E. Otegbeye, A. Arnold, Z. Stadler, M. Robson, C. Aghajanian, K. Offit, R. Barakat, N. Kauff
Memorial Sloan-Kettering Cancer Center, New York, NY

246 – Acceptability of salpingectomy alone as risk-reducing surgery for BRCA mutation carriers
L. Holman1, S. Friedman2, M. Daniels1, C. Sun1, K. Lu1
1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL

247 – Patterns of care for risk-reducing salpingo-oophorectomy (RRSO) for BRCA mutation carriers and subsequent surveillance
I. Cass, C. Walsh, J. Lester, A. Li, B. Karlan
Cedars-Sinai Medical Center, Los Angeles, CA

248 – Comparing coordinated versus sequential salpingo-oophorectomy for BRCA1 and BRCA2 mutation carriers with breast cancer
J. Chapman1, A. Panighetti2, S. Hwang3, B. Crawford4, B. Powell5, J. Chan4, L. Chen4
1University of California San Francisco, San Francisco, CA, 2University of Washington Medical Center, Seattle, WA, 3Duke University Medical Center, Durham, NC, 4UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 5Kaiser Permanente, San Francisco, CA

249 – Cancer risks in women from BRCA-negative hereditary breast and ovarian cancer families
K. Long, M. Pike, E. Otegbeye, A. Arnold, Z. Stadler, M. Robson, R. Barakat, K. Offit, D. Chi, N. Kauff
Memorial Sloan-Kettering Cancer Center, New York, NY

250 – Is BRCA mutation screening a cost-effective strategy to improve targeted therapy in serous epithelial ovarian cancer?
J. Scalici1, J. Straughn2, J. Estes2, C. Leath2, M. Finan1, R. Rocconi1
1University of South Alabama-Mitchell Cancer Institute, Mobile, AL, 2University of Alabama at Birmingham, Birmingham, AL

251 – Frequencies of nonovarian cancers within the Gilda Radner Familial Ovarian Cancer Registry
R. Brightwell, A. Miller, S. Poblete, K. Odunsi, S. Lele
Roswell Park Cancer Institute, Buffalo, NY

Abstracts 252 – 264: Novel Surgical Techniques

252 – Comparison of aortic nodes yields and metastasis rates above and below the inferior mesenteric artery in clinically low stage carcinomas
K. O’Hanlan1, J. Ferry1, M. Chivukula2, M. O’Holleran3
1Laparoscopic Institute for Gynecologic Oncology, Portola Valley, CA, 2Magee-Women’s Hospital of UPMC, Pittsburgh, PA, 3General Surgery Associates, San Carlos, CA

253 – Impact of obesity on surgical outcomes of laparoscopic radical pelvic lymphadenectomy for women with cervical, endometrial, or ovarian cancer
K. O’Hanlan1, J. Ferry1, M. Chivukula2, M. Harrington1, M. O’Holleran3
1Laparoscopic Institute for Gynecologic Oncology, Portola Valley, CA, 2Magee-Women’s Hospital of UPMC, Pittsburgh, PA, 3General Surgery Associates, San Carlos, CA

254 – Transperitoneal versus retroperitoneal approach for staging aortic lymphadenectomy
K. O’Hanlan1, J. Ferry1, M. Chivukula2, M. O’Holleran3
1Laparoscopic Institute for Gynecologic Oncology, Portola Valley, CA, 2Magee-Women’s Hospital of UPMC, Pittsburgh, PA, 3General Surgery Associates, San Carlos, CA

255 – Does IORT at the time of pelvic exenteration impact survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?
F. Backes, L. Huffman, B. Tierney, E. Eisenhauer, D. Cohn, J. Fowler
The Ohio State University, Columbus, OH

256 – CyberKnife for single extracranial ovarian or uterine cancer metastases
B. Collins1, T. Kelly2, W. Barnes3
1Medstar Georgetown University Hospital, Department of Radiation Medicine, Washington, DC, 2Medstar Georgetown University Hospital, Washington, DC, 3Medstar Georgetown University Hospital, Division of Gynecologic Oncology, Washington, DC

257 – First case of pregnancy following a modified Strassman procedure
S. Saso1, O. Naji1, M. Seckl1, Y. Abdallah1, L. Ismail1, Y. Thum2, J. Smith1
1Imperial College London, London, United Kingdom, 2The Lister Hospital, London, United Kingdom

258 – A 10-year experience of cecal neovagina procedures for the restoration of sexual function on a gynecologic oncology service
B. Khulpateea, D. Silver
The Women’s Institute for Gynecologic Cancer and Special Pelvic Surgery, Phillipsburg, NJ

259 – Urologic outcomes following modified Indiana pouch during pelvic exenteration for gynecologic malignancies
V. Andikyan, F. Khoury-Collado, E. Hobeika, S. Lee, N. Abu-Rustum, Y. Sonoda, J. Sandhu, R. Barakat, B. Bochner, D. Chi
Memorial Sloan-Kettering Cancer Center, New York, NY

260 – Modified gluteal fold advancement V-Y flap for vulvar reconstruction after surgery for vulvar malignancies
V. Di Donato, A. Musella, C. Bracchi, I. Palaia, F. Bellati, F. Tomao, A. Besharat, S. Visentin, P. Benedetti Panici
Department of Gynecologic Oncology – Sapienza University, Rome, Italy

261 – Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer
S. Sandadi, K. Long, V. Andikyan, J. Vernon, Y. Sonoda, R. Barakat, D. Chi
Memorial Sloan-Kettering Cancer Center, New York, NY

262 – Distal pancreatectomy as part of cytoreductive surgery in patients with ovarian cancer: Morbidity and evolution of a surgical technique
M. Lim, Y. Kim, H. Yoo, S. Seo, S. Kang, S. Park
National Cancer Center, Goyang-si, Republic of Korea

263 – The blood supply of the remaining uterus after radical abdominal trachelectomy
X. Wu, J. Tang, L. Jin, Z. Jiang
Fudan University Shanghai Cancer Center, Shanghai, China

264 – PET probe-assisted surgical debulking in patients with recurrent gynecologic tumors
S. Bush, H. Williams, C. Aksu, B. Rungruang, M. Macfee, S. Ghamande
Georgia Health Sciences University, Augusta, GA

Abstracts 265 – 286: Ovarian Cancer

265 – Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma
K. Matsuo1, S. Todd2, K. Yoshino3, S. Mabuchi3, D. Im2, N. Rosenshein2, A. Sood4, L. Roman1
1University of Southern California, Los Angeles, CA, 2Mercy Medical Center, Baltimore, MD, 3Osaka University, Suita, Japan, 4The University of Texas, MD Anderson Cancer Center, Houston, TX

266 – How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter
L. Elit1, C. Charles2, A. Gafni2, I. Gold3, J. Ranford4, S. Tedford Gold5
1Juravinski Cancer Centre, Hamilton, Ontario, Canada, 2McMaster University, Hamilton, Ontario, Canada, 3Faculties of Medicine, Ottawa, Ontario, Canada, 4University of Waterloo, Waterloo, Ontario, Canada, 5Core Research and Consulting, Ottawa, Ontario, Canada

267 – Analysis of survivorship in high-risk patients on treated on GOG-218
R. Coleman1, R. Burger2, M. Brady3, M. Bookman4, J. Fowler5, M. Birrer6, G. Fleming7, R. Mannel8, B. Monk9
1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Fox Chase Cancer Center, Philadelphia, PA, 3Roswell Park Cancer Institute, Buffalo, NY, 4The University of Arizona Cancer Center, Tucson, AZ,5The Ohio State University, Columbus, OH, 6Massachusetts General Hospital/Harvard University, Boston, MA, 7University of Chicago, Chicago, IL, 8University of Oklahoma, Oklahoma City, OK, 9Creighton University School of Medicine, Phoenix , AZ

268 – Pretreatment assessment of primary ovarian cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography
H. Chung1, S. Kang2, N. Park3, Y. Song3, J. Kim3
1Seoul National University College of Medicine, Seoul, Republic of Korea, 2Konkuk University Hospital, Seoul, Republic of Korea, 3Seoul National University, Seoul, Republic of Korea,

269 – Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer
R. Previs1, J. Kilgore2, R. Craven2, G. Broadwater1, S. Bean1, S. Wobker2, M. DiFurio2, P. Gehrig2, A. Alvarez-Secord1
1Duke University Medical Center, Durham, NC, 2University of North Carolina School of Medicine, Chapel Hill, NC

270 – Factors leading to racial disparities in treatment and outcomes of epithelial ovarian cancer
B. Erickson, J. Martin, M. Shah, J. Fauci, L. Daily, D. Pasko, C. Walters, C. Leath, J. Straughn
University of Alabama at Birmingham, Birmingham, AL

271 – Long-term survival outcomes in patients with advanced epithelial ovarian, fallopian tube, and primary peritoneal malignancies as related to preoperative nutritional status
S. Harris1, J. Elder1, I. Podzielinski2, M. Schwartz1, F. Ueland1, J. Hoff1, L. Baldwin1, J. VanNagell1, B. Huang1, R. Miller1
1University of Kentucky, Lexington, KY, 2Fort Wayne Gynecologic Oncology, Ft Wayne, IN

272 – Optimal but visible residual disease: Is extensive debulking warranted?
J. Barlin, K. Long, E. Tanner, G. Gardner, M. Leitao, D. Levine, Y. Sonoda, N. Abu-Rustum, R. Barakat, D. Chi
Memorial Sloan-Kettering Cancer Center, New York, NY

273 – Which is the price of an upper abdomen optimal cytoreduction for advanced ovarian cancer? Analysis of complications
V. Di Donato, A. Casorelli, M. Fischetti, L. Salerno, C. Marchetti, F. Bellati, P. Giorgia, I. Palaia, P. Benedetti Panici
Department of Gynecologic Oncology – Sapienza University, Rome, Italy

274 – Comprehensive epigenetic analysis of Notch pathway in high-grade serous ovarian cancer
W. Hu, C. Ivan, J. Bottsford-Miller, B. Zand, H. Dalton, A. Nick, G. Lopez-Berestein, R. Coleman, K. Bagglerly, A. Sood
1The University of Texas, MD Anderson Cancer Center, Houston, TX

275 – A cost-effectiveness analysis of the adjuvant treatment of advanced epithelial ovarian carcinoma
E. Schroeder1, X. Burbano-Levy2, D. Wrenn1, J. De La Garza1, A. Garcia-Soto1, S. Schuman1, F. Simpkins1, J. Pearson1, J. Lucci1, J. Diaz1
1University of Miami Sylvester Cancer Center, Miami, FL, 2Zilonis Health, Inc., Miami, FL

276 – Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival
J. Cohen, A. Tran, B. Rimel, C. Walsh, I. Cass, B. Karlan, A. Li
Cedars-Sinai Medical Center, Los Angeles, CA

277 – Serous tubal vs. ovarian vs. peritoneal vs. uterine cancers – A study of 12,369 women
E. Simons1, K. Blansit2, T. Kiet2, R. Brooks2, S. Ueda2, L. Chen2, D. Kapp1, J. Chan2
1Stanford University Medical Center, Stanford, CA, 2UCSF Comprehensive Cancer Center, San Francisco, CA

278 – Comparative effectiveness of upfront treatment strategies for advanced-stage ovarian cancer
J. Wright1, C. Ananth2, T. Herzog2, W. Burke2, Y. Lu2, S. Lewin2, A. Neugut2, D. Hershman2
1Columbia University, New York, NY, 2Columbia University College of Physicians and Surgeons, New York, NY

279 – Impact of underweight after the completion of primary treatment on prognosis in patients with advanced-stage epithelial ovarian cancer
S. Kim1, H. Kim2, H. Chung2, J. Kim2, N. Park2, Y. Song2
1Seoul National University College of Medicine, Seoul, Republic of Korea

280 – Determinants of emergency department (ED) diagnosis of ovarian cancer and subsequent surgical morbidity and mortality
A. Punjabi, S. Koroukian, N. Schiltz, J. Barnholz-Sloan, K. Zanotti
Case Western Reserve – MacDonald Women’s Hospital, Cleveland, OH

281 – Abstract Withdrawn at Author’s Request

282 – The efficacy of serum multivariate markers to diagnose ovarian cancer in patients with ovarian tumor
S. Lee1, M. Kyung2, D. Kim3, J. Kim3, Y. Kim3, Y. Kim3, J. Nam3
1University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 2Hallym University Sacred Heart Hospital Chuncheon, Chuncheon, Republic of Korea, 3University of Ulsan, Asan Medical Center, Seoul, Republic of Korea

283 – Serous tubal intraepithelial carcinoma frequency in endometriosis-associated epithelial ovarian cancer
J. Nakayama, A. VanRegenmorter, K. Atkins, L. Duska
University of Virginia Health System, Charlottesville, VA

284 – Altered recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancer
M. Dao, L. Alwan, B. Goff, J. Liao
University of Washington Medical Center, Seattle, WA

285 – Ovarian low-malignant potential tumors: The clinical value of serum CA-125
G. Rao1, S. Phelps2, J. Schorge3
1University of Maryland, Baltimore, MD, 2Texas Oncology, Dallas, TX, 3Massachusetts General Hospital/Harvard University, Boston, MA

286 – Metabolic tumor volume measured by preoperative 18F-fluorodeoxyglucose positron emission tomography and computed tomography predicts for recurrence in endometrial cancer
S. Shim, D. Kim, S. Lee, J. Park, J. Lee, J. Kim, Y. Kim, Y. Kim, J. Nam
University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Abstracts 287 – 298: Ovarian Cancer (Chemotherapy)

287 – Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab
L. Randall1, R. Burger2, H. Nguyen3, G. Kong3, M. Bookman4, G. Fleming5, B. Monk6, R. Mannel7, M. Birrer8
1UC Irvine Medical Center, Orange, CA, 2Fox Chase Cancer Center, Philadelphia, PA, 3Genentech, Inc, San Francisco, CA, 4The University of Arizona Cancer Center, Tucson, AZ, 5University of Chicago, Chicago, IL,6Creighton University School of Medicine, Omaha, NE, 7University of Oklahoma, Oklahoma City, OK, 8Massachusetts General Hospital/Harvard University, Boston, MA

288 – Expression and serum immunoreactivity identify cancer/testis genes 55 and 57 as immunotherapy targets in ovarian cancer
C. Liu1, A. Miliotto2, S. Daudi2, A. Groman2, S. Lele2, K. Odunsi2
1SUNY University at Buffalo and Roswell Park Cancer Institute, Buffalo, NY, 2Roswell Park Cancer Institute, Buffalo, NY

289 – A dose-dense carboplatin and paclitaxel regimen is highly active in the treatment of recurrent ovarian cancer
J. Hunn1, M. Tenney1, A. Hoekstra2, A. Puglisi3, C. Kirschner3, J. Hurteau3, G. Rodriguez3
1University of Chicago, Chicago, IL, 2West Michigan Cancer Center, Kalamazoo, MI, 3NorthShore University Health System, Lake Forest, IL

290 – The effectiveness of intraperitoneal chemotherapy in treating retroperitoneal stage IIIC ovarian carcinoma
T. May1, M. Shoni2, K. Esselen1, J. Rauh-Hain1, A. Vitonis1, N. Horowitz1
1Brigham & Women’s Hospital, Boston, MA, 2Dana-Farber Cancer Institute, Boston, MA

291 – Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer – A phase I study
R. Salani, D. O’Malley, L. Copeland, D. Cohn, J. Fowler, E. Eisenhauer
The Ohio State University, Columbus, OH

292 – Patterns of crossover to antiangiogenesis agents in recurrent ovarian cancer patients: An analysis of a Gynecologic Oncology Group ancillary data study (GOG#218, abstract)
J. Chan1, J. Java2, B. Monk3, R. Coleman4, M. Birrer5, C. Aghajanian6, M. Bookman7, R. Burger8
1UCSF Comprehensive Cancer Center, San Francisco, CA, 2Gynecologic Oncology Group, Buffalo, NY, 3Creighton University School of Medicine, Phoenix, AZ, 4The University of Texas, MD Anderson Cancer Center, Houston, TX, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6Memorial Sloan-Kettering Cancer Center, New York, NY, 7The University of Arizona, Tuscon, AZ, 8Fox Chase Cancer Center, Philadelphia, PA

293 – Common genes and pathways associated with in vitro/in vivo ovarian cancer chemo-response and overall survival
N. Bou Zgheib1, D. Marchion2, P. Judson Lancaster2, R. Wenham2, S. Apte2, J. Lancaster2, J. Gonzalez Bosquet2
1University of South Florida College of Medicine, Tampa, FL, 2H. Lee Moffitt Cancer Center, Tampa, FL

294 – Prognostic significance of dose reductive chemotherapy in epithelial ovarian cancer
K. Han1, H. Chung1, J. Kim1, N. Park1, Y. Song2, S.B. Kang4
1Seoul National University Hospital, Seoul, Republic of Korea, 2Cancer Research Institute, Seoul National University College of Medicine, World Class University, Seoul, Republic of Korea, 3Women’s Gynecologic Oncology Center, Konkuk University Hospital, Seoul, Republic of Korea

295 – Successful oxaliplatin salvage for recurrent ovarian cancer after carboplatin/cisplatin allergy
S. Taylor, T. Beck, T. Krivak, K. Zorn, J. Kelley, R. Edwards
Magee-Women’s Hospital of UPMC, Pittsburgh, PA

296 – Platinum dosing for epithelial ovarian cancer: Is it appropriate to use actual body weight?
J. Martin, M. Shah, B. Erickson, L. Daily, D. Pasko, C. Walters, J. Fauci, K. Bevis
University of Alabama at Birmingham, Birmingham, AL

297 – Hyperthermic intraperitoneal chemotherapy with carboplatin for recurrent epithelial ovarian cancer: A pilot study
T. Sueblinvong1, P. Argenta1, M. Geller1, L. Downs1, A. Jonson1, L. Carson1, J. Ivy1, P. Judson Lancaster2
1University of Minnesota, Minneapolis, MN, 2Moffit Cancer Center, Tampa, FL

298 – A phase I study of intraperitoneal carboplatin with intravenous paclitaxel and bevacizumab in patients with previously untreated epithelial ovarian carcinoma or primary peritoneal carcinoma
D. O’Malley, E. Eisenhauer, G. McCann, R. Salani, F. Backes, L. Copeland, J. Fowler, D. Cohn
The Ohio State University, Columbus, OH

Abstracts 299 – 334: Ovarian Cancer (Translational Research/Basic Science)

299 – Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
D. Roque, N. Buza, M. Glasgow, E. Ratner, D. Silasi, M. Azodi, T. Rutherford, P. Schwartz, A. Santin
Yale University School of Medicine, New Haven, CT

300 – Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96
J. Fauci1, A. Londono-Joshi1, J. Straughn1, F. Sabbatino2, Y. Wang2, S. Ferrone2, D. Buchsbaum1
1University of Alabama at Birmingham, Birmingham, AL, 2University of Pittsburgh Cancer Institute, Pittsburgh, PA

301 – The COX-2 inhibitor, celecoxib, exhibits antitumorigenic and antimetastatic effects for ovarian cancer in vitro and in vivo
A. Suri1, K. Schuler2, C. Zhou2, Y. Zong2, P. Gehrig2, V. Bae-Jump2
1University of North Carolina Medical School, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

302 – Role of ARID1A for the clinicopathologic characteristics of clear cell carcinoma (CCC) of the ovary
H. Abou-Taleb, K. Yamaguchi, M. Mandai, K. Yamanoi, Y. Amano, N. Matsumura, T. Baba, Y. Yoshioka, J. Hamanishi, I. Konishi
Graduate School of Medicine, Kyoto University, Kyoto, Japan

303 – Celecoxib and paclitaxel synergistically induce apoptosis in the human ovarian cancer cell line OVCAR-3
H. Kim, G. Yim, Y. Kim
Women’s Life Medical Science, Department of Obstetrics and Gynecology, Yonsei University, College of Medicine, Seoul, Republic of Korea

304 – Novel genetic alterations in serous borderline tumors of the ovary revealed by whole exome sequencing
J. Boyd, B. Luo, S. Peri, B. Wirchansky, L. Hughes, C. Forsythe, H. Wu, M. Morgan
Fox Chase Cancer Center, Philadelphia, PA

305 – Tumor-specific targeting with novel LXY-30 peptide-linked nanoparticles for paclitaxel delivery in ovarian cancer mouse xenograft model
N. Suby1, K. Xiao2, Y. Yi2, W. Xiao2, L. Tiglao2, K. Lam2
1UC Davis Medical Center, Sacramento, CA, 2University of California – Davis, Sacramento, CA

306 – Decreased 53BP1 expression predicts improved survival in sporadic ovarian carcinoma
K. Pennington1, A. Wickramanayake1, B. Norquist1, S. Kaufmann2, C. Pennil1, R. Garcia1, K. Agnew1, P. Welcsh1, E. Swisher1
1University of Washington Medical Center, Seattle, WA, 2Mayo Clinic, Rochester, MN

307 – Deception of suppression: Unexpected effects of tristetraprolin in ovarian cancer
B. Zand, C. Ivan, C. Pecot, R. Rupaimoole, H. Dalton, J. Bottsford-Miller, W. Hu, A. Nick, A. Sood
The University of Texas, MD Anderson Cancer Center, Houston, TX

308 – PI3K pathway activation, thromboembolism and survival in ovarian clear cell carcinoma
E. Diaz1, H. Agadjanian2, H. Nassanian2, A. Walts2, C. Miller2, D. Zajchowski3, B. Karlan2, S. Orsulic2, C. Walsh2
1UCLA/Cedars-Sinai Hospitals, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3The Clearity Foundation, San Diego, CA

309 – Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: Expression of GRIA2 predicts better survival
C. Choi1, Y. Lee1, W. Kim1, T. Kim1, J. Lee1, B. Kim1, D. Bae1, J. Park1, A. Yoon1, M. Kim2
1Samsung Medical Center, Seoul, Republic of Korea, 2Samsung Medical Center, Changwon, Republic of Korea

310 – Neuropathic pain inhibitor Kindolor augments efficacy of gemcitabine and paclitaxel in ovarian cancer cell lines, allowing reduced chemotherapy concentration
C. Anderson, D. Hicks, H. Scarborough, L. Vanderlinden, B. Tabakoff, K. Behbakht, M. Spillman
University of Colorado, Aurora, CO

311 – Meso-TR3: A novel TRAIL-based therapeutic with target-dependent activation at tumor site
G. Garg, M. Powell, D. Mutch, J. Gibbs, P. Goedegebuure, W. Hawkins, D. Spitzer
Washington University School of Medicine, St. Louis, MO

312 – Expression of stress-induced phosphoprotein-1 (STIP-1) was associated with tumor progression and poor prognosis in epithelial ovarian cancer
M. Lee1, H. Cho2, J. Chung3, S. Hewitt3, D. Chay4, Y. Kwon1, J. Kim2
1Kangdong Sacred Heart Hospital, Hallym University, Seoul, Republic of Korea, 2Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 3National Cancer Institute, Bethesda, MD, 4Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

313 – A water-soluble analog of triptolide induces ovarian cancer cell death in vitro and in vivo
C. Rivard Hunt, M. Geller, C. Evans, R. Vogel, S. Ramakrishnan, A. Saluja
University of Minnesota, Minneapolis, MN

314 – The oncogenic role of human epididymis protein (HE4): Promotion of tumorigenesis, cell survival, and cisplatin resistance in ovarian cancer in an in vivo mouse model
E. Hill, R. Singh, T. Horan, N. Yano, S. Chu, Q. Mao, K. Kim, T. Lange, G. Lambert-Messerlian, R. Moore
Women & Infants Hospital, Brown University, Providence, RI

315 – Proteomic analysis of matched formalin-fixed, paraffin-embedded specimens in patients with advanced serous ovarian carcinoma
A. Smith1, M. Sun2, R. Bhargava1, N. Stewart2, M. Flint3, T. Krivak1, M. Strange4, W. Bigbee5, N. Yates6, K. Zorn1
1Magee-Women’s Hospital of UPMC, Pittsburgh, PA, 2University of Pittsburgh Biomedical Mass Spectrometry Center for the Health Sciences, Pittsburgh, PA, 3University of Pittsburgh Cancer Institute, Pittsburgh, PA,4Women’s Cancer Research Center, Pittsburgh, PA, 5Women’s Cancer Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, 6Department of Cell Biology & Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA

316 – A novel cMET inhibitor, MK8033, potentiates the activity of carboplatin/paclitaxel in ovarian cancer cell lines
D. Marchion, I. Ramirez-Diaz, N. Bou Zgheib, Y. Xiong, X. Stickles, P. Judson Lancaster, J. Gonzalez Bosquet, R. Wenham, S. Apte, J. Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL

317 – Molecular characterization of polyphyllin D, a Chinese herb that sensitizes ovarian cancers cells to platinum therapy
E. Al Sawah, D. Marchion, Y. Xiong, I. Ramirez-Diaz, F. Abbasi, N. Bou Zgheib, A. Hakam, R. Wenham, J. Lancaster, P. Judson Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL

318 – Nonascites-forming advanced-stage serous ovarian cancer is related to a superior epithelial antigen presentation and enhanced infiltrating T-cell response
T. Feigenberg1, B. Clarke2, C. Virtanen3, M. Letarte4, A. Kollara5, B. Rosen6, M. Bernardini7, T. Brown5, K. Murphy6
1Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada, 2Toronto General Hospital, Toronto, Ontario, Canada, 3Ontario Cancer Institute Genomics Centre (OCIG), Toronto, Ontario, Canada, 4Hospital for Sick Children, Toronto, Ontario, Canada, 5Samuel Lunenfeld Reaserch Institute, Toronto, Ontario, Canada, 6Princess Margaret Hospital, Toronto, Ontario, Canada, 7Division of Gynecologic Oncology University Health Network (UHN), Toronto, Ontario, Canada

319 – Drug screening identifies growth inhibition of ovarian tumor-initiating cells by niclosamide
H. Lai1, Y. Yo2, Y. Wang1, C. Balch3, R. Huang4, C. Chang1, K. Nephew5, T. Huang6
1Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, 2Lab of Epigenetics and Cancer Stem Cells, National Defense Medical Center, Taipei, Taiwan,3Indiana University, School of Medicine, Indianapolis, IN, 4National Yang-Ming University, National Defense Medical Center, Taipei, Taiwan, 5Indiana University Simon Cancer Center; Indiana University School of Medicine, Indianapolis, IN, 6Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX

320 – Mapping the chemokine microenvironment in ovarian cancer
E. Zsiros1, M. Feldman2, R. Frank2, I. Hagemann3, H. Lee2, J. Tanyi2, G. Coukos2
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Medical Center, Philadelphia, PA, 3Washington University, St. Louis, MO

321 – Endometrioid ovarian carcinoma has a distinct gene expression profile separate and unique from serous ovarian carcinoma
J. Stephan, T. Neff, T. Bair, S. Park, D. Bender, A. Ahmed, K. De Geest, A. Dupuy, M. Goodheart
University of Iowa Hospitals and Clinics, Iowa City, IA

322 – Methylomic profiling of ovarian cancer-initiating cells identifies DNA methylation as a prognostic biomarker
H. Lai1, Y. Liao1, R. Huang2
1Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, 2National Yang-Ming University, National Defense Medical Center, Taipei, Taiwan

323 – Human leukocyte antigen polymorphisms predict NY-ESO-1 tumor antigen serology and overall survival in epithelial ovarian cancer
S. Daudi, M. Brady, A. Miliotto, J. Matsuzaki, S. Lele, K. Odunsi
Roswell Park Cancer Institute, Buffalo, NY

324 – Dual mTOR inhibition demonstrates antiproliferative and chemosensitizing effects in chemoresistant high-grade papillary serous ovarian cancer
F. Musa, I. Giuroiu, S. Blank, S. Korets, J. Curtin, R. Schneider
New York University Medical Center, New York, NY

325 – Chemokine receptors enhance T-cell vaccine cell homing to ovarian cancer
E. Zsiros1, P. Duttagupta2, T. Garrabrant2, B. Levine2, J. Tanyi2, L. Kandalaft2, G. Coukos2
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Medical Center, Philadelphia, PA

326 – The omental microenvironment promotes ovarian cancer metastasis by enhancing the CD-133-mediated self-assembly of ovarian cancer spheroids
M. Brewer1, G. Sun1, M. Anderson2, W. Shan2, M. Zhong3
1University of Connecticut Health Center, Farmington, CT, 2Baylor College of Medicine, Houston, TX, 3Southern Medical University, Quangzhou, China

327 – Disulfiram’s antineoplastic effects on ovarian cancer bulk tumor cells and the stem cell population: A study in ovarian cancer cell lines and in rodents
Y. Rezk, K. Yang, S. Bai, K. McLean, C. Johnston, R. Reynolds, R. Buckanovich
University of Michigan, Ann Arbor, MI

328 – Abstract withdrawn at author’s request.

329 – Characterizing the activity of MK2206 in ovarian cancer and defining the molecular determinants of response
N. Bou Zgheib, D. Marchion, Y. Xiong, E. Al Sawah, I. Ramirez-Diaz, P. Judson Lancaster, J. Gonzalez Bosquet, R. Wenham, S. Apte, J. Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL

330 – Gene expression levels in archived FFPE ovarian carcinoma samples: Comparison of qPCR with tissue microarray in a 9-core pathway predictive treatment model in serous ovarian carcinoma
W. Bradley1, K. Eng2, C. Kendziorski2, M. Le3, C. Mackinnon3, J. Rader3
1Medical College of Wisconsin, Milwaukee, WI, 2University of Wisconsin, Madison, WI, 3University of Wisconsin & Medical College of Wisconsin, Wauwatosa, WI

331 – Pathways involved in doxorubicin sensitivity in vitro correlate with overall survival from ovarian cancer
N. Bou Zgheib, Y. Xiong, D. Marchion, X. Stickles, E. Al Sawah, P. Judson Lancaster, J. Gonzalez Bosquet, R. Wenham, S. Apte, J. Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL

332 – Prognostic significance of B cells and pSTAT3 in patients with ovarian cancer
S. Pal, J. Deng, V. Jove, H. Lee, X. Liu, C. Yang, T. Dellinger, W. Zhang, M. Wakabayashi, H. Yu
City of Hope Medical Group, Duarte, CA

333 – Ovulation induction with gonadotropins accelerates tumor growth and alters the intratumoral T-cell population in an ovarian cancer model
C. Morse1, V. Jha2, M. Mainigi2, D. Olalare2, T. Ord2, S. Adams3
1University of Washington Medical Center, Seattle, WA, 2University of Pennsylvania Medical Center, Philadelphia, PA, 3University of New Mexico, Albuquerque, NM

334 – The HIV protease inhibitor ritonavir induces cell cycle arrest and apoptosis in the A2780 ovarian cancer cell line in vitro and in vivo
B. Winterhoff1, A. Teoman1, L. Freyer1, A. Von Bismarck1, S. Dowdy1, B. Schmalfeldt2, S. Kumar1, V. Shridhar1
1Mayo Clinic, Rochester, MN, 2Technical University of Munich, Munich, Germany

Abstracts 335 – 342: Palliative Care

335 – The effect of religiosity on death anxiety and end-of-life care discussions among gynecologic oncology patients
A. Brown1, M. Shen2, R. Giuntoli3, T. Diaz-Montes3
1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Mount Sinai School of Medicine, New York, NY, 3Johns Hopkins Medical Institutions, Baltimore, MD

336 – The prevalence and impact of invasive procedures towards the end of life on patients referred to hospice care
J. Stine, K. Doll, D. Moore, L. Van Le, E. Ko, J. Soper, D. Clarke Pearson, V. Bae-Jump, P. Gehrig, K. Kim
University of North Carolina at Chapel Hill, Chapel Hill, NC

337- A novel approach to palliative care and end-of-life decision-making: A patient-centered website to promote health care decision-making
M. Geller, S. Petzel, R. Vogel, D. Chan, M. McClellan, M. Gerber, J. Cragg, J. Jacko, F. Sainfort
University of Minnesota, Minneapolis, MN

338 – Palliative surgical procedures in the last 6 months of life: Effect on quality care measures
M. Lopez Acevedo, J. Sandoval, P. Lee, G. Broadwater, A. Berchuck, L. Havrilesky
Duke University Medical Center, Durham, NC

339 – The impact of outpatient hospice discussions on subsequent inpatient hospitalization in gynecologic oncology patients
K. Doll, J. Stine, D. Moore, L. Van Le, V. Bae-Jump, W. Brewster, J. Soper, J. Boggess, P. Gehrig, K. Kim
University of North Carolina School of Medicine, Chapel Hill, NC

340 – The use of medical resources at the end-of-life among gynecologic cancer patients at an urban, public hospital
E. Wu1, A. Rogers2, L. Ji1, R. Sposto1, T. Church1, D. Tripathy1, Y. Lin1
1University of Southern California, Los Angeles, CA, 2University of California Davis, Sacramento, CA

341 – At the end of life: Optimizing quality of care for women dying of cervical cancer
M. Courtney-Brooks, L. Duska
University of Virginia Health System, Charlottesville, VA

342 – Beyond the dark side of the moon: Evaluating the quality of web-based information at the end of life
E. Stevens1, M. Henretta2
1SUNY/Downstate Medical Center, Brooklyn, NY, 2Stony Brook University Hospital, Stony Brook, NY

Abstracts 343 – 348: Public Health

343 – Free testosterone is driver of cancer aggressiveness: Evidence from US population studies
M. Kopf, S. He, R. Samuelson, M. Mariani, C. Ferlini, S. Shahabi
Danbury Hospital, Danbury, CT

344 – Vitamin D-related effects on gynecologic cancer diagnosis and prognosis trends: Ultraviolet radiation index associations in United States cancer registries
J. Harris, C. Starnes, L. Baldwin, C. DeSimone, F. Ueland, J. van Nagell, Jr, R. Ware Miller
University of Kentucky, Lexington, KY

345 – Occupational exposures and ovarian cancer: A national population-based cohort study
L. Eiriksson1, M. Harris2, J. Hardt3, M. Tjepkema4, P. Peters4, P. Demers3
1University of Toronto, Toronto, Ontario, Canada, 2Ryerson University, Toronto, Ontario, Canada, 3Occupational Cancer Research Centre, Toronto, Ontario, Canada, 4Statistics Canada, Ottawa, Ontario, Canada

346 – Comparison of the environmental impact of commonly used surgical approaches to hysterectomy
D. Woods, S. Isani, T. McAndrew, N. Nevadunsky, J. Hou, G. Goldberg, D. Kuo
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

347 – Regional variation in the incidence of gynecologic malignancies (GM) in the US
T. Korenaga, K. Ward, M. McHale, C. Saenz, S. Plaxe
UCSD- The Moores Cancer Center, La Jolla, CA

348 – Using social media as a research platform for rare gynecologic tumors
T. Zaid, J. Burzawa, K. Schmeler, J. Brown, L. Ramondetta, M. Frumovitz
The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstracts 349 – 360: Quality of Life

349 – Pretreatment oncology reproductive counseling improves quality of life and satisfaction with health care in survivors of gynecologic cancers
J. Chan1, M. Cedars1, J. Letourneau2, M. Rosen1, L. Chen1, J. Chan1
1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

350 – Lower-limb drainage mapping for lymphedema risk reduction after pelvic lymphadenectomy for endometrial cancer
A. Bats, C. Bensaïd, C. Nos, M. Le Frère-Belda, M. Collignon, M. Faraggi, F. Lecuru
Hôpital Européen Georges-Pompidou, Paris, France

351 – Pilot study of the PARO therapeutic robot demonstrates decreased pain, fatigue, and anxiety among patients with recurrent ovarian carcinoma
R. Eskander1, K. Tewari1, K. Osann1, T. Shibata2
1University of California Irvine Medical Center, Orange, CA, 2University of Tokyo, Tokyo, Japan

352 – An interactive website for patients with ovarian cancer and their care givers: Can we improve quality of life?
M. Geller, S. Petzel, R. Vogel, M. McClellan, J. Jacko, J. Cragg, M. Gerber, D. Chan, F. Sainfort
University of Minnesota, Minneapolis, MN

353 – Pilot study evaluating the integration of psychological assessment among women undergoing care for gynecologic malignancies
T. Diaz-Montes1, M. Gerardi Fairbairn2, A. Jernigan3, A. Belozer3, R. Giuntoli3, M. Kimmel3
1Johns Hopkins Medical Institutions, Owings Mills, MD, 2Johns Hopkins Hospital, Baltimore, MD, 3Johns Hopkins Medical Institutions, Baltimore, MD

354 – Idiographic assessment of quality of life of women with high risk gynecological malignancies
N. Nevadunsky, G. Kaur, L. Spoozak, B. Rapkin, K. Taylor, P. Selwyn, G. Goldberg
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

355 – Self-reported physical activity among gynecologic oncology patients in an outpatient setting: A pilot survey
P. Gehrig1, L. Song2, W. Thompson2, D. Moore2, S. Yeo2
1University of North Carolina School of Medicine, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

356 – Reintegration of cervical cancer survivors: A survey of women’s health providers
L. Garcia1, L. Viveros2, M. Kagawa-Singer3, C. Holschneider4, M. Amneus2
1Olive View-UCLA Medical Center, Los Angeles, CA, 2Olive View-UCLA Medical Center, Sylmar, CA, 3University of California Los Angeles Fielding School of Public Health, Los Angeles , CA, 4UCLA School of Medicine, Los Angeles, CA

357 – Sexual function in older cancer survivors
J. Varughese, E. Erekson, K. Tran, M. Ciarleglio, D. Patel, E. Ratner
Yale University School of Medicine, New Haven, CT

358 – Improvement in quality of life after robotic surgery results in patient satisfaction
P. Soliman, C. Sun, S. Westin, N. Fleming, K. Schmeler, A. Nick, P. Ramirez
The University of Texas, MD Anderson Cancer Center, Houston, TX

359 – The impact of acupuncture and massage on perception, symptom management, and quality of life in women with gynecologic malignancy
A. Jairam-Thodla1, C. DeCroes2, R. Bers2, C. Passaglia2, J. Schink2
1Northwestern Memorial Hospital, Chicago, IL, 2Northwestern University/Prentice Women’s Hospital, Chicago, IL

360 – Physician preferences for involvement in survivorship care: Are benign gynecologists ready?
M. Schlumbrecht1, A. Milbourne2, C. Sun2, M. Huang2, D. Bodurka2
1Banner MD Anderson, Phoenix, AZ, 2The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstracts 361 – 369: Rare Tumors

361 – Presentation and management of borderline ovarian tumors: Should mucinous tumors be managed differently?
J. Black, N. Yoo, T. Rutherford, F. Tavassoli, E. Ratner, N. Buza, M. Azodi, P. Schwartz
Yale University School of Medicine, New Haven, CT

362 – Glassy cell carcinoma of the cervix: A systematic review and meta-analysis
C. Guitarte, E. Stevens, O. Abulafia, Y. Lee
SUNY/Downstate Medical Center, Brooklyn, NY

363 – The impact of obesity and adjuvant chemotherapy regimens on women with ovarian granulosa cell tumors
A. Suri1, E. Carter2, J. Edwards3, B. Erickson4, W. Huh4, A. Alvarez-Secord3, L. Havrilesky3, K. Kim5, N. Horowitz2, P. Gehrig5
1University of North Carolina Medical School, Chapel Hill, NC, 2Brigham & Women’s Hospital, Boston, MA, 3Duke University Medical Center, Durham, NC, 4University of Alabama at Birmingham, Birmingham, AL,5University of North Carolina at Chapel Hill, Chapel Hill, NC

364 – Sentinel lymph nodes and vulvovaginal melanoma: Comparison of sentinel lymph node protocols
E. Euscher, A. Malpica
The University of Texas, MD Anderson Cancer Center, Houston, TX

365 – Molecular alterations of PIK3CA in uterine malignant mesodermal mixed tumors and clear cell carcinomas
S. Bashir1, J. Gaofeng2, A. Joshi2, A. Yang2, A. Yemelyanova3, T. Caputo1, K. Holcomb1, L. Ellenson1, D. Gupta1
1Weill Medical College of Cornell University and New York Presbyterian Medical Center, New York, NY, 2Weill Medical College of Cornell University, New York, NY, 3Johns Hopkins Hospital, Baltimore, MD

366 – Uterine leiomyosarcomas have reproducible molecular subtypes that correlate with survival
J. Barlin1, Q. Zhou1, M. Leitao1, M. Bisogna1, N. Olvera1, M. Hensley1, G. Schwartz1, J. Boyd2, L. Qin1, D. Levine1
1Memorial Sloan-Kettering Cancer Center, New York, NY, 2Fox Chase Cancer Center, Philadelphia, PA

367 – Uterine adenosarcoma: A closer look at a rare disease
A. Carroll, P. Ramirez, S. Westin, P. Soliman, M. Munsell, A. Nick, K. Schmeler, M. Frumovitz, A. Klopp, N. Fleming
The University of Texas, MD Anderson Cancer Center, Houston, TX

368 – Vulvovaginal melanoma: An institutional experience
C. St. Clair, S. Wethington, E. Jewell, N. Abu-Rustum, D. Chi, M. Leitao, R. Barakat, K. Alektiar, R. Carvajal, Y. Sonoda
Memorial Sloan-Kettering Cancer Center, New York, NY

369 – Institutional review of primary lymphoma of the female genital tract: A 32-year experience
A. Ahmad1, J. Varughese2, P. Hui2, A. Santin2, M. Azodi2, D. Silasi2, P. Schwartz2, T. Rutherford2, E. Ratner2
1Yale New Haven Hospital, New Haven, CT, 2Yale University School of Medicine, New Haven, CT

Abstracts 370 – 389: Robotic Surgery

370 – Feasibility and perioperative outcomes of robotic-assisted surgery for the management of recurrence disease in gynecologic oncology: A multi-institutional study
P. Escobar1, A. Talati2, A. Aylward3, J. Magrina4, S. Nahas4, M. Martino5, R. Barakat3, A. Nickles Fader6, M. Leitao3
1The Cleveland Clinic Foundation, Cleveland, OH, 2Case Western Reserve – MacDonald Women’s Hospital, Cleveland, OH, 3Memorial Sloan-Kettering Cancer Center, New York, NY, 4Mayo Clinic Scottsdale, Scottsdale, AZ, 5Lehigh Valley Hospital Cedar Crest, Allentown, PA, 6Johns Hopkins Medical Institutions, Baltimore, MD

371 – Physical strain and minimally invasive surgery: Is the robotic platform the answer?
W. Burke1, P. Ramirez2, M. Greer2, R. Naumann3, M. Frumovitz2
1Columbia University Medical Center, New York, NY, 2MD Anderson, Houston, TX, 3Carolinas Medical Center, Charlotte, NC

372 – Comparison of perioperative and clinical outcomes in the management of epithelial ovarian cancer: Robotic vs. abdominal approach
G. Feuer1, P. Alvarez2, S. Rao2, N. Lakhi1, M. Burrell2
1Atlanta Gynecologic Oncology, Atlanta, GA, 2Southestern Gynecologic Oncology LLC, Atlanta, GA

373 – Robotic surgery for the management of ovarian cancer
T. Evans1, T. Randall2, I. Wilkinson-Ryan3
1University of Pennsylvania Health Systems, Pennsylvania Hospital, Philadelphia, PA, 2University of Pennsylvania Medical Center, Philadelphia, PA, 3Washington University School of Medicine, St. Louis, MO

374 – Low incidence of port-site metastasis after robotic-assisted surgery for endometrial cancer staging
D. Barraez1, T. McElrath2, D. Kredentser2, T. Morrissey2, P. Timmins2
1Berkshire OB/GYN Associates PC, Pittsfield, MA, 2Women’s Cancer Care Associates, Albany, NY

375 – Trends in surgical training among gynecologic oncology fellows before and after the introduction of robotic surgery
J. Knight1, A. Talati2, S. Rao1, P. Escobar1
1The Cleveland Clinic Foundation, Cleveland, OH, 2Case Western Reserve University School of Medicine, Cleveland, OH

376 – Feasibility of robotic extraperitoneal para-aortic lymphadenectomy for gynecologic cancer
A. Bats, C. Bensaïd, A. Achouri, L. Makke, C. Nos, F. Lecuru
Hôpital Européen Georges-Pompidou, Paris, France

377 – Rate of bowel herniation in patients undergoing robotic surgery
N. Goldman1, J. Wright2, S. Lewin2, T. Herzog2, W. Burke1
1The Valley Hospital, Paramus, NJ, 2Columbia University Presbyterian Hospital, New York, NY

378 – Advancing robotic sentinel lymph node detection with indocyanine green (ICG) fluorescence: Optimal concentration for discrimination of the sentinel node
K. Levinson1, H. Mahdi2, L. David2, P. Escobar2
1Cleveland Clinic, Cleveland, OH, 2The Cleveland Clinic Foundation, Cleveland, OH

379 – Is robotic hysterectomy really less painful than traditional laparoscopy?
S. Lange, N. Rozario, J. Hall, R. Higgins, D. Tait, R. Naumann
Carolinas Medical Center, Charlotte, NC

380 – Learning curve associated with becoming proficient in completing a robotic-assisted total laparoscopic hysterectomy: A single-institution gynecologic oncology fellowship experience
S. Sandadi, J. Gadzinski, S. Lee, D. Chi, E. Jewell, C. Brown, G. Gardner, R. Barakat, M. Leitao
Memorial Sloan-Kettering Cancer Center, New York, NY

381 – Incidence of port-site hernias and/or dehiscence in robotic-assisted procedures in gynecologic oncology patients
J. Boone, J. Fauci, E. Barr, J. Estes, K. Bevis
University of Alabama at Birmingham, Birmingham, AL

382 – Surgical complications associated with robotic, laparoscopic, and open approaches in endometrial cancer: A study of 6,560 patients
K. Fuh1, K. Blansit1, R. Brooks1, S. Ueda1, L. Chen1, X. Yu2, J. Chan1
1UCSF Comprehensive Cancer Center, San Francisco, CA, 2The University of Memphis, Memphis, TN

383 – Does robotic hysterectomy increases the incidence of lymphovascular space invasion in endometrial cancer?
Z. Al-Wahab, S. Bandyopadhyay, R. Ali-Fehmi, S. Seward, S. Elshatanoufy, R. Hanna, A. Munkarah, R. Morris
Wayne State University, Detroit, MI

384 – A health care economic analysis of robotic surgery for endometrial cancer: A nationwide study of 420 hospitals
K. Fuh1, X. Yu2, K. Blansit3, R. Brooks3, S. Ueda3, L. Chen3, J. Chan3
1Stanford University Medical Center, Stanford, CA, 2The University of Memphis, Memphis, TN, 3UCSF Comprehensive Cancer Center, San Francisco, CA

385 – Ergonomic evaluation of gynecologic oncologists performing robotic surgery
R. Craven1, J. Franasiak1, P. Mosaly2, P. Gehrig1
1University of North Carolina School of Medicine, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

386 – Hospital characteristics associated with the utilization of robotic surgery in endometrial cancer
C. Jones1, C. Jones1, K. Blansit1, J. Ram2, R. Brooks1, S. Ueda1, L. Chen1, D. Kapp3, X. Yu4, J. Chan1
1UCSF Comprehensive Cancer Center, San Francisco, CA, 2Georgetown University, Washington, DC, 3Stanford University Medical Center, Stanford, CA, 4The University of Memphis, Memphis, TN

387 – Comparison of vaginal cuff closure outcomes in patients having robotic-assisted total laparoscopic hysterectomy: V-Loc vs. Vicryl
M. Martino, R. Reynolds, A. El Haraki, R. Morcrette, K. Langston, G. Kainz, R. Boulay, M. Thomas
Lehigh Valley Health Network, Allentown, PA

388 – Port-site metastases after robotic surgery for gynecologic malignancy
C. Walters1, J. Straughn1, C. Landen1, J. Estes1, W. Huh1, K. Kim2
1University of Alabama at Birmingham, Birmingham, AL, 2University of North Carolina School of Medicine, Chapel Hill, NC

389 – Vaginal cuff complications decreased in total robotic vs. laparoscopic hysterectomy in cancer and noncancer patients: Bidirectional barbed vs. conventional suture
E. Salom1, J. Tangir1, H. Gerber2, M. Hagazy1, N. Echavarri Botero1, K. Perez1, E. Bonier1, D. Henriquez Romero1, M. Penalver1
1Florida International University College of Medicine, Miami, FL, 2Palmetto General Hospital, Hialeah, FL

Abstracts 390 – 395: Translational Research/Basic Science

390 – Circulating endothelial progenitor cells in gynecologic cancer
J. Song, Y. Chung, Y. Kim, J. Lee, N. Lee, H. Bae
Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Republic of Korea

391 – An innovative in silico method to identify agents that target pathways of human cancer chemoresistance
D. Marchion, I. Ramirez-Diaz, Y. Xiong, E. Al Sawah, F. Abbasi, N. Bou Zgheib, X. Stickles, J. Gonzalez Bosquet, R. Wenham, J. Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL

392 – Identifying drug repurposing opportunities to target genes and molecular pathways associated with cancer cell proliferation
I. Ramirez, D. Marchion, Y. Xiong, E. Al Sawah, N. Bou Zgheib, B. Boac, X. Stickles, A. Hakam, S. Apte, J. Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL

393 – Identification and characterization of novel Müllerian-specific cancer associated antigens
T. Zaid, R. Schmandt, S. Mok
The University of Texas, MD Anderson Cancer Center, Houston, TX

394 – KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease
S. Westin1, C. Sun1, N. Pal1, F. Janku1, A. Tsimberidou1, G. Falchook1, D. Hong1, K. Lu1, R. Coleman1, R. Kurzrock2
1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2University of California San Diego, Ashland, OR

395 – Progression-free survival can be predicted in epithelial ovarian cancer patients by in vitro chemosensitivity testing using the histoculture drug response assay – A prospective observational study in a single institution
P. Jung, D. Kim, J. Kim, Y. Kim, J. Nam, S. Lee, J. Park, Y. Kim
Asan Medical Center, Seoul, Republic of Korea

Abstracts 396 – 401: Vulvar Cancer

396 – Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry
C. Craig1, C. Lin2, S. Fedewa2, K. Virgo2, J. Farley3, B. Monk3, D. Chase3
1St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 2American Cancer Society, Inc., Atlanta, GA, 3Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, AZ

397 – Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins
Y. Ioffe1, K. Foster2, B. Erickson2, D. Mutch1, M. Powell1, P. Thaker1, A. Hagemann1, M. Conner1, W. Huh2, L. Massad1
1Washington University School of Medicine, St. Louis, MO, 2University of Alabama at Birmingham, Birmingham, AL

398 – Patterns of inguinal lymph node metastasis in patients with vulvar cancer
G. Baiocchi, F. Cestari, A. Lavorato-Rocha, B. Maia, R. Rocha, I. Rodrigues, E. Fukazawa, L. Kumagai, L. Badiglian-Filho, C. Faloppa
AC Camargo Cancer Hospital, Sao Paulo, Brazil

399 – Prognostic factors of recurrence in patients with advanced squamous cell carcinoma of the vulva treated with primary surgery and adjuvant radiotherapy: An institutional experience
N. Skampardonis1, N. Thomakos1, D. Zacharakis1, M. Sotiropoulou2, G. Vlachos3, D. Haidopoulos3, A. Rodolakis3, A. Antsaklis1
11st Department of Obstetrics and Gynecology, University of Athens, Alexandra Hospital, Athens, Greece, 2Department of Pathology, Alexandra Hospital, Athens, Greece, 31st Department of Obstetrics and Gynecology, University of Athens, Gynecologic Oncology Unit, Athens, Greece

400 – Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer
L. Divine, B. Erickson, C. Leath, J. Straughn
University of Alabama at Birmingham, Birmingham, AL

401 – Lymphatic mapping and sentinel lymph node dissection is cost-effective compared to complete lymphadenectomy in the management of early-stage vulvar cancer
G. McCann1, D. Cohn1, E. Jewell2, L. Havrilesky3
1The Ohio State University, Columbus, OH, 2Memorial Sloan-Kettering Cancer Center, New York, NY, 3Duke University Medical Center, Durham, NC